Point Biopharma
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Point Biopharma was a radiopharmaceutical company developing radioligand therapies for cancer. Its pipeline included clinical and preclinical-stage programs, led by PNT2002 - a PSMA-directed therapy for metastatic castration-resistant prostate cancer - and PNT2003, a somatostatin-receptor-directed therapy for neuroendocrine tumors. The company operated a radiopharmaceutical manufacturing campus in Indianapolis and an R&D center in Toronto.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Acquisition agreed
On October 3, 2023, Eli Lilly agreed to acquire Point Biopharma for $1.4 billion ($12.50 per share in cash, an 87% premium).
- Acquisition completed
Lilly's tender offer expired on December 22, 2023; the company completed the acquisition through a second-step merger and Point's stock was delisted from Nasdaq.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.